| Old Articles: <Older 4181-4190 Newer> |
|---|
 |
The Motley Fool
September 28, 2007
Brian Lawler |
Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs.   |
BusinessWeek
October 8, 2007
Arlene Weintraub |
Will Pharma Finally Have To Fess Up? New efforts are under way to limit or make public drug company's billions in giveaways to doctors. |
The Motley Fool
September 27, 2007
Brian Orelli |
Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note. |
The Motley Fool
September 27, 2007
Brian Lawler |
FDA Repeats Itself With Cephalon's Fentora In the wake of a letter from Cephalon to health-care practitioners, the FDA has issued a press release and a public health advisory of the dangers of misusing the company's pain drug Fentora. Investors, take note. |
The Motley Fool
September 27, 2007
Brian Orelli |
Foreign Invasion of the Biochip Market A consortium of Japanese companies including Toshiba, and Canon are planning on jointly developing biochips for research and diagnostic purposes. |
The Motley Fool
September 27, 2007
Billy Fisher |
Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps. |
The Motley Fool
September 27, 2007
Brian Lawler |
A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note. |
The Motley Fool
September 27, 2007
Brian Lawler |
ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note. |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
| <Older 4181-4190 Newer> Return to current articles. |
